Marstacimab Sustains Long-Term Bleeding Decrease

Source link :

Marstacimab, a novel, investigational monoclonal antibody, shows long-term safety and efficacy in the prevention of bleeding events in patients with hemophilia A as well as B without inhibitors, potentially adding to the toolbox for hemophilia A and representing a first of its kind therapy for hemophilia B. “In the long-term extension study treatment with marstacimab […]

Author : News Health

Publish date : 2024-06-28 05:43:06

Copyright for syndicated content belongs to the linked Source.